AstraZeneca PLC (AZN)vsRidgetech, Inc. (RDGT)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
RDGT
Ridgetech, Inc.
$0.83
-1.59%
HEALTHCARE · Cap: $3.39M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 46332% more annual revenue ($61.37B vs $132.16M). AZN leads profitability with a 17.0% profit margin vs -0.9%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
RDGT
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+82.8%
Fair Value
$10.36
Current Price
$0.83
$9.53 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Every $100 of equity generates 30 in profit
Conservative balance sheet, low leverage
Revenue surging 21.4% year-over-year
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : RDGT
The strongest argument for RDGT centers on Price/Book, Return on Equity, Debt/Equity. Revenue growth of 21.4% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : RDGT
The primary concerns for RDGT are EPS Growth, Market Cap, Free Cash Flow.
Key Dynamics to Monitor
AZN profiles as a mature stock while RDGT is a growth play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.20 — expect wider price swings.
RDGT is growing revenue faster at 21.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 39/100), backed by strong 17.0% margins. RDGT offers better value entry with a 82.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Ridgetech, Inc.
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
China Jo-Jo Drugstores, Inc. is a retailer and wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. The company is headquartered in Hangzhou, the People's Republic of China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?